Are plasma ghrelin and PYY concentrations associated with obesity-related depression?

Endokrynologia Polska

Volumn 61, Issue 2, 2010, Pages 174-177

  Olszanecka Glinianowicz, Magdalena ^a   Kocełak, Piotr ^a   Wikarek, Tomasz ^a   Gruszka, Wojciech ^a   Da̧browski, Piotr ^a   Chudek, Jerzy ^a   Zahorska Markiewicz, Barbara ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Metabolic Management Clinic WAGA   (Poland)

Author keywords

Depression; Ghrelin; Obesity; Peptide YY

Indexed keywords

GHRELIN; PEPTIDE YY;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BECK ANXIETY INVENTORY; BLOOD LEVEL; BLOOD SAMPLING; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; EVALUATION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IMPEDANCE; OBESITY;

DEPRESSION; FEMALE; GHRELIN; HUMANS; MIDDLE AGED; NEUROPEPTIDE Y; OBESITY; PEPTIDE YY;

EID: 77953533509     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Specker S, de Zwaan M, Raymond N et al. Psychopathology in subgroups of obese women with and without eating disorders. Comp Psychiatry 1994; 35: 185-190. (Pubitemid 24154019)
2. Hsu LK, Mulliken B, McDonagh B et al. Binge eating disorder in extreme obesity. Int J Obes 2002; 26: 1398-1403. (Pubitemid 35221890)
3. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Da̧browski P et al. Depression level in obese persons before starting the complex group weight loss programme. Int J Soc Psychiatry 2009; 55: 407-413.
4. Wurtman JJ. Depression and weight gain: the serotonin connection. J Affect Disord 1993; 29: 183-192.
5. Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav 2007; 91: 449-458.
6. Veith RC, Lewis N, Linares OA et al. Sympathetic nervous system activity in major depression. Basal and desipramine - induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1994; 51: 411-422.
7. Redrobe JP, Dumont Y, Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci 2002; 71: 2921-2937. (Pubitemid 35221402)
8. Strombom U, Krotkiewski M, Blennow K et al. The concentrations of monoamine metabolites and neuropeptides in the cerebrospinal fluid of obese women with different body fat distribution. Int J Obes 1996; 20: 361-368. (Pubitemid 26110412)
9. Lambert GW, Vaz M, Cox HS et al. Human obesity is associated with chronic elevation in brain 5-hydroxytryptamine turnover. Clin Sci 1999; 96: 191-197. (Pubitemid 29094939)
10. Wang GJ, Volkow ND, Logan J et al. Brain dopamine and obesity. Lancet 2001; 357: 354-357.
11. Zahorska-Markiewicz B, Obuchowicz E, Waluga M et al. Neuropeptide Y in obese women during treatment with adrenergic modulation drugs. Med Sci Monit 2001; 7: 403-408. (Pubitemid 32476052)
12. Yang K, Xie G, Zhang Z et al. Levels of serum interleukin (IL)-6, IL-1beta, tumor necrosis factor-alpha and leptin and their correlation in depression. Aust N Z J Psychiatry 2007; 41: 266-273. (Pubitemid 46705742)
13. Kim YK, Na KS, Shin KH et al. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 30: 1044-1053. (Pubitemid 46810095)
14. Miller GE, Rohleder N, Stetler C, Kirschbaum C. Clinical depression and regulation of the inflammatory response during acute stress. Psychosom Med 2005; 67: 679-687. (Pubitemid 41396011)
15. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Kocelak P et al. Is chronic inflammation - a possible cause of obesity-related depression? Mediators Inflam 2009 doi: 10.1155/2009/439107
16. Lutter M, Sakata I, Osborne-Lawrence S. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci 2008; 11: 752-753 (Pubitemid 351896679)
17. Burdyga G, Varro A, Dimaline R et al. Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1289-G1297. (Pubitemid 43788312)
18. Proietto J, Gantz I, Carr RD et al. A two-year study to assess the efficacy, safety, and tolerability of Teranabant in obese patients: 52 week results. Int J Obes 2008; 32 (Suppl 1): 22.
19. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913.
20. Eaton K, Sallee FR, Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr. Top. Med. Chem. 2007; 7: 1645-1659.
21. Wynne K, Stanley S, Bloom SR. The gut and regulation of body weight. J Clin Endocrinol Metab 2004; 89: 2576-2582.
22. Tschop M, Weyer C, Tataranni PA et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-709. (Pubitemid 32242624)
23. Battherham RL, Cowley MA, Small CJ. et al. Gut hormone PYY(3-36) physiologically inhibits food inteake. Nature 2000; 418: 650-654.
24. Zahorska-Markiewicz B, Mizia-Stec K, Olszanecka-Glinianowicz M et al. Effect of weight reduction on serum ghrelin and TNFa concentrations in obese women. Eur J Inter Med 2004; 15: 172-175. (Pubitemid 38900563)
25. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Kocełak P et al. The effect of weight loss treatment using Orlistat on serum concentrations of ghrelin and peptide YY. Int J Obes 2007; 31 (Suppl 1): 80.
26. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Da̧browski P et al. The effect of the complex group weight loss programme on depression level in obese persons. Int J Obes 2007; 31 (Suppl 1): 181.
27. Tender B, Atmaca A, Aliyazicioglu Y et al. Serum ghrelin levels but not GH, IGF-1 and IGFBP-3 levels are altered in patients with fibromyalgia syndrome. Joint Bone Spine 2007; 74: 477-481.
28. Pinar M, Gulsun M, Tasci I et al. Maprotiline induced weight gain in depressive disorder: changes in circulating ghrelin and adiponectin levels and insulin sensitivity. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 135-139.
29. Widerlöv E, Lindström LH, Wahlestedt C et al. Neuropeptide Y and peptide YY as possible cerebrospinal fluids markers for major depression and schizophrenia, respectively. J Psychiatr Res 1988; 22: 69-79.